GlaxoSmithKline Invests in French Production Facility
ePT--the Electronic Newsletter of Pharmaceutical Technology
London (Sept. 29)-GlaxoSmithKline will invest more than ? 500 million in a vaccine-manufacturing plant in St-Amand-Les-Eaux, France. The investment will expand the company?s production capacity in formulation, filling, freeze-drying, and packaging in response to increasing worldwide demand for pediatric and adult vaccines.
London (Sept. 29)-GlaxoSmithKline (GSK, Brentford, UK, www.gsk.com) will invest more than € 500 million in a vaccine-manufacturing plant in St-Amand-Les-Eaux, France. The investment will expand the company’s production capacity in formulation, filling, freeze-drying, and packaging in response to increasing worldwide demand for pediatric and adult vaccines.
The St-Amand-Les-Eaux plant will manufacture GSK’s vaccines for meningitis, Streptococcus pneumoniae, and non-typeable Haemophilus influenzae. In addition, the site will help produce many of GSK’s developmental vaccines such as “Cervarix,” a vaccine against human papilloma virus with potential to prevent cervical cancer, and a modified influenza vaccine.
The French facility will include a lyophilization plant for stabilizing vaccines. The location also will be equipped with a liquid plant for filling syringes and vials, a packing plant and warehouse, a power plant, and quality-control laboratories.
The St-Amand-Les-Eaux facility is the latest investment in GSK’s international vaccines industrial network and follows expansions and acquisitions of vaccine-production sites in Dresden, Germany; Marietta, Pennsylvania; and Singapore. The French plant is expected to be operational in 2011.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
